HK1144532A1 - Tartrate salts or complexes of quinazoline based egfr inhibitors containing a zinc binding moiety - Google Patents

Tartrate salts or complexes of quinazoline based egfr inhibitors containing a zinc binding moiety

Info

Publication number
HK1144532A1
HK1144532A1 HK10111104.8A HK10111104A HK1144532A1 HK 1144532 A1 HK1144532 A1 HK 1144532A1 HK 10111104 A HK10111104 A HK 10111104A HK 1144532 A1 HK1144532 A1 HK 1144532A1
Authority
HK
Hong Kong
Prior art keywords
complexes
binding moiety
egfr inhibitors
zinc binding
inhibitors containing
Prior art date
Application number
HK10111104.8A
Other languages
English (en)
Chinese (zh)
Inventor
Xiong Cai
Changgeng Qian
Haixiao Zhai
Original Assignee
Curis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curis Inc filed Critical Curis Inc
Publication of HK1144532A1 publication Critical patent/HK1144532A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255—Tartaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
HK10111104.8A 2007-09-10 2010-11-29 Tartrate salts or complexes of quinazoline based egfr inhibitors containing a zinc binding moiety HK1144532A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97105607P 2007-09-10 2007-09-10
PCT/US2008/056393 WO2009035718A1 (en) 2007-09-10 2008-03-10 Tartrate salts or complexes of quinazoline based egfr inhibitors containing a zinc binding moiety

Publications (1)

Publication Number Publication Date
HK1144532A1 true HK1144532A1 (en) 2011-02-25

Family

ID=40452375

Family Applications (1)

Application Number Title Priority Date Filing Date
HK10111104.8A HK1144532A1 (en) 2007-09-10 2010-11-29 Tartrate salts or complexes of quinazoline based egfr inhibitors containing a zinc binding moiety

Country Status (8)

Country Link
US (3) US7846938B2 (el)
EP (1) EP2190287B1 (el)
JP (1) JP5474792B2 (el)
AU (1) AU2008299896B2 (el)
CA (1) CA2698944C (el)
ES (1) ES2526718T3 (el)
HK (1) HK1144532A1 (el)
WO (1) WO2009035718A1 (el)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101535279B (zh) 2006-09-11 2015-05-20 柯瑞斯公司 含锌结合基的喹唑啉基egfr抑制剂
CN101570516B (zh) * 2009-04-14 2011-01-05 重庆威尔德·浩瑞医药化工有限公司 一种制备4-(3-氯-4-氟苯基胺基)-7-甲氧基-6-[3-(4-吗啉基)丙氧基]喹唑啉的方法
CN102452988B (zh) * 2010-10-27 2016-01-27 中国科学院化学研究所 一种喹唑啉衍生物及其制备方法
US9295676B2 (en) 2011-03-17 2016-03-29 The Trustees Of The University Of Pennsylvania Mutation mimicking compounds that bind to the kinase domain of EGFR
US9321759B2 (en) 2011-03-17 2016-04-26 The Trustees Of The University Of Pennsylvania Methods and use of bifunctional enzyme-building clamp-shaped molecules
US20140229256A1 (en) 2013-02-11 2014-08-14 Solutran Product substantiation using approved product list system and method
CN102276500A (zh) * 2011-05-05 2011-12-14 西安交通大学 水杨酰胺类抗肿瘤化合物及其合成方法和用途
CN103906732A (zh) * 2011-10-28 2014-07-02 株式会社钟根堂 用作hdac抑制剂的异羟肟酸酯衍生物以及包含所述衍生物的药物组合物
WO2013159698A1 (zh) * 2012-04-26 2013-10-31 深圳信立泰药业股份有限公司 稠环喹唑啉羟肟酸类化合物及其作为抗肿瘤药物的应用
CN102898315B (zh) * 2012-11-05 2015-01-28 上海毕得医药科技有限公司 3-乙炔基-4-氟苯胺的制备方法
US10552861B2 (en) 2013-02-11 2020-02-04 Solutran, Inc. Dual redemption path with shared benefits system and method
JP2017524034A (ja) 2014-08-08 2017-08-24 フォーサイト・ビジョン フォー・インコーポレーテッドＦｏｒｓｉｇｈｔ Ｖｉｓｉｏｎ４， Ｉｎｃ． 受容体型チロシンキナーゼ阻害剤の安定で可溶な製剤およびその調製の方法
CN105693630B (zh) * 2016-03-10 2018-02-16 田静 一种吉非替尼中间体的制备方法
US20220371990A1 (en) * 2019-09-08 2022-11-24 Hadasit Medical Research Services And Developmect Ltd. Anti-fibrotic compounds and use thereof

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5369108A (en) * 1991-10-04 1994-11-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
AU661533B2 (en) * 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
EP0626373B1 (en) * 1993-05-26 1998-12-23 Sumitomo Pharmaceuticals Company, Limited Quinazolinone derivatives
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9508537D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
SK285141B6 (sk) * 1996-02-13 2006-07-07 Astrazeneca Uk Limited Použitie chinazolínového derivátu, chinazolínový derivát, spôsob jeho prípravy a farmaceutická kompozícia, ktorá ho obsahuje
US6777217B1 (en) * 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
EE05345B1 (et) 1999-02-10 2010-10-15 Astrazeneca Ab Kinasoliini derivaadid angiogeneesi inhibiitoritena
US7230000B1 (en) * 1999-10-27 2007-06-12 Cytokinetics, Incorporated Methods and compositions utilizing quinazolinones
UA74803C2 (uk) * 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
TWI310684B (en) * 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
EP1366027B1 (en) 2001-02-26 2006-09-20 McGILL UNIVERSITY Combi-molecules having signal transduction inhibitory properties and dna damaging properties
AU2003257666A1 (en) * 2002-08-23 2004-03-11 Kirin Beer Kabushiki Kaisha COMPOUND HAVING TGFss INHIBITORY ACTIVITY AND MEDICINAL COMPOSITION CONTAINING THE SAME
US7250514B1 (en) * 2002-10-21 2007-07-31 Takeda San Diego, Inc. Histone deacetylase inhibitors
WO2004064718A2 (en) 2003-01-23 2004-08-05 T.K. Signal Ltd. Irreversible inhibitors of egf receptor tyrosine kinases and uses thereof
PE20040945A1 (es) * 2003-02-05 2004-12-14 Warner Lambert Co Preparacion de quinazolinas substituidas
AU2004276055A1 (en) * 2003-09-25 2005-04-07 Astrazeneca Ab Quinazoline derivatives
GB0322409D0 (en) * 2003-09-25 2003-10-29 Astrazeneca Ab Quinazoline derivatives
WO2005097137A2 (en) 2004-03-31 2005-10-20 The Scripps Research Institute Advanced quinazoline based protein kinase inhibitors
EP1855760A2 (en) 2005-02-03 2007-11-21 TopoTarget UK Limited Combination therapies using hdac inhibitors
AU2006235487B2 (en) * 2005-04-12 2011-12-22 Elan Pharma International Limited Nanoparticulate quinazoline derivative formulations
RU2007142007A (ru) 2005-04-14 2009-05-20 Новартис Вэксинес Энд Дайэгностикс Инк. (Us) 2-аминохиназолин-5-оны
ITMI20050729A1 (it) * 2005-04-22 2006-10-23 Endura Spa Nuova formulazione biologicamente attiva
WO2007131364A1 (en) 2006-05-16 2007-11-22 Mcgill University Hybrid molecules having mixed vitamin d receptor agonism and histone deacetylase inhibitory properties
AU2007296745B2 (en) * 2006-09-11 2011-12-01 Curis, Inc. Quinazoline based EGFR inhibitors
CN101535279B (zh) 2006-09-11 2015-05-20 柯瑞斯公司 含锌结合基的喹唑啉基egfr抑制剂
US7547781B2 (en) 2006-09-11 2009-06-16 Curis, Inc. Quinazoline based EGFR inhibitors containing a zinc binding moiety
EP2061772A4 (en) * 2006-09-11 2011-06-29 Curis Inc MULTIFUNCTIONAL SMALL MOLECULES AS PROLIFERATION-ACTIVE ACTIVE SUBSTANCES
JP5583406B2 (ja) 2006-10-28 2014-09-03 メチルジーン インコーポレイテッド ヒストンデアセチラーゼの阻害剤
US8119616B2 (en) 2007-09-10 2012-02-21 Curis, Inc. Formulation of quinazoline based EGFR inhibitors containing a zinc binding moiety

Also Published As

Publication number Publication date
JP2010539082A (ja) 2010-12-16
US20110053963A1 (en) 2011-03-03
US20130338167A1 (en) 2013-12-19
ES2526718T3 (es) 2015-01-14
AU2008299896A1 (en) 2009-03-19
US8846912B2 (en) 2014-09-30
JP5474792B2 (ja) 2014-04-16
WO2009035718A1 (en) 2009-03-19
AU2008299896B2 (en) 2012-02-02
EP2190287A4 (en) 2012-07-25
CA2698944C (en) 2015-06-16
CA2698944A1 (en) 2009-03-19
EP2190287A1 (en) 2010-06-02
US20090076022A1 (en) 2009-03-19
US7846938B2 (en) 2010-12-07
EP2190287B1 (en) 2014-10-29

Similar Documents

Publication Publication Date Title
HK1144532A1 (en) Tartrate salts or complexes of quinazoline based egfr inhibitors containing a zinc binding moiety
IL197451A0 (en) Quinazoline based egfr inhibitors containing a zinc binding moiety
EP2061469A4 (en) CHINAZOLIN BASED EGFR HEMMER WITH A ZINC BONDING PART
IL197447A0 (en) Tyrosine kinase inhibitors containing a zinc binding moiety
EP2194787A4 (en) VEGFR HEMMER WITH A ZINC BONDING PART
EP2061758A4 (en) A ZINC BINDING GROUP CONTAINING SUBSTITUTED 2-INDOLINONE AS PTK INHIBITORS
IL200596A0 (en) Tetrahydroisoquinolines as tumour growth inhibitors
EP2166859A4 (en) QUINAZOLINE SALT COMPOUNDS
IL194871A0 (en) Iap bir domain binding compounds
DK1997793T3 (da) Heteromolekylære metal-humussyre-komplekser (chelater)
IL200779A0 (en) Pdgfr beta-specific inhibitors
PL2010496T3 (pl) 4-Anilinochinolino-3-karboksyamidy jako inhibitory kinazy CSF-1R
ZA201006641B (en) Mtor inhibitor salt forms
EP2084139A4 (en) OXAZOLIDINIUM COMPOUNDS AND USE AS HYDRATINE HIBITORS
EP2379510A4 (en) quinazolinone
PT2137217E (pt) Métodos para inibir a ligação da endosialina a ligandos
IL189809A0 (en) Glucuronate salt of a piperazine compound
EP2079839A4 (en) ASSESSMENT OF COLORECTAL CARCINOMA RISK
EP2001590A4 (en) POLYIMIDAZOLIUM SALTS AND POLY-NHC-METAL COMPLEXES
EP2136829A4 (en) INHIBITORS OF BINDING TO A PROTEIN KINASE
IL213742A0 (en) Substituted quinazoline compounds
PL1890300T3 (pl) Powlekana osłona kabla
PT2373805E (pt) Composições de reagentes de baixo teor de sal total e sistemas para biossensores
IL204945A0 (en) Compositions and methods for inhibiting tumor progression
EP2035439A4 (en) RISK ASSESSMENT FOR COLORECTAL CANCER

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20190310